Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03554486 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy
A Phase 4 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 4
- Development phase
- 27
- Enrollment target
NCT03554486: Completed Phase 4 study, sponsored by Stanford University.
NCT03554486 is a Phase 4 study that has completed, run by Stanford University. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03554486, a Phase 4 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 27 participants
- Enrollment target
Study Summary
This is a pilot outpatient study conducted at Stanford to obtain preliminary data on how Fiasp® works in a closed-loop system and to determine if any changes need to be made to the 670G pump to optimize the use of Fiasp®.
Interventions
- DRUG Novolog
- DRUG Fiasp
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2018-07-23 |
| Est. Completion | 2019-03-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03554486
The ClinicalTrials.gov registry entry for NCT03554486 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Novolog is the first listed.
NCT03554486 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03554486 about?
NCT03554486 is a clinical study titled "Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy". This is a pilot outpatient study conducted at Stanford to obtain preliminary data on how Fiasp® works in a closed-loop system and to determine if any changes need to be made to the 670G pump to optimize the use of Fiasp®.
What is the current status of trial NCT03554486?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 27 participants. The study started on 2018-07-23. Estimated completion is 2019-03-30.
What interventions are being tested in trial NCT03554486?
The interventions under investigation include: Novolog (DRUG), Fiasp (DRUG).
Who is sponsoring clinical trial NCT03554486?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.